



ASX ANNOUNCEMENT

30 January 2009

Second South African Patent Granted

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** today announced that the VitroGro® patent “Skin Regeneration System” has been granted by the Republic of South Africa Patent office.

This follows the earlier granting of another of the VitroGro® patents “Growth Factor Complexes and Modulation of Cell Migration and Growth” by the Republic of South Africa Patent office in early 2007 and by the Intellectual Property Office of New Zealand in 2006.

The VitroGro® patent “Growth Factor Complex” was granted in both Australia and New Zealand during 2005.

As previously announced (see **ASX: TIS VitroGro® Patent Granted in USA, 13 January 2009**) all claims in the VitroGro® patent “Growth Factor Complex” have now also been granted by the United States Patent and Trademark Office.

The CEO of Tissue Therapies, Dr Steven Mercer said, “After considerable effort over a number of years, it is particularly satisfying to now have multiple VitroGro® patents granted in different jurisdictions, including the United States. We are all now looking forward to a continuing flow of successful patent applications throughout the world.”

He went on to explain that applications to protect the family of VitroGro® patents have been lodged in USA, Canada, EU, Japan, China (including Hong Kong), South Korea, India, Australia, New Zealand and South Africa. Trademark protection of VitroGro® as also been sought in the same jurisdictions.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com